Navigation Links
Cardium Presents First Quarter 2011 Financial Results and Reports on Near-Term Milestones
Date:5/16/2011

ent population; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. *Note: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.Copyright 2011 Cardium Therapeutics, Inc.  All rights reserved.For Terms of Use Privacy Policy, please visit www.cardiumthx.com.Cardium Therapeutics® Generx®, Cardionovo™ and MedPodium™ are trademarks of Cardium Therapeutics, Inc.Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen™, Excellarate™, Osteorate™, Appexium™,Linee™, Alena™, Cerex™ and Nutra-Apps™ are trademarks of Tissue Repair Company.(Cereboost is a trademark of Naturex Inc.)(Phase 2® is used with permission and protected under U
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
2. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
3. Cardium Announces Appointment of Paul A. Foster, M.D. to Lead Generx and Excellarate Late-Stage Development Activities
4. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
5. Cardiums InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
6. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
7. Cardium Announces Completion of Patient Recruitment in Phase 2b Clinical Trial of Excellarate(TM) for the Potential Treatment of Diabetic Foot Ulcers
8. Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study
9. Cardium Reports Non-Healing Wounds Continue to Challenge Patients and Healthcare Providers
10. Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development
11. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015 Immune Pharmaceuticals, Inc. ("Immune") (NASDAQ: ... Daniel Teper , will present live at VirtualInvestorConferences.com on ... TIME:   11:30AM EDT LINK:    http://tinyurl.com/aug6-pre-imnp ... event where investors are invited to ask the company ... as well as the association,s "virtual trade booth." If ...
(Date:8/3/2015)... Shire plc (LSE: SHP, ... has acquired New York -based, ... With the acquisition, Shire acquires the global rights ... iodine (PVP-I) and 0.1% dexamethasone), a therapy in ... an ocular surface condition commonly referred to as ...
(Date:8/2/2015)... 2015  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... 3 clinical trial met its primary endpoint, showing ... cancer patients with carcinoid syndrome that is not ... Telotristat etiprate was discovered using Lexicon,s gene science, ... company,s first discovery to complete a pivotal Phase ...
Breaking Medicine Technology:Immune Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com August 6 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 2Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 3Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 4Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 5Shire Acquires Privately Held Foresight Biotherapeutics Inc., Boosting Ophthalmics Portfolio with Late-Stage Asset 6Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 2Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 3Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 4Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 5Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome 6
... NEW ORLEANS, June 6 Eli Lilly and Company (NYSE: ... study results of LY2189265, its investigational glucagon-like peptide 1 (GLP-1) ... diabetes. These data will be presented as part of the ... , , In the Phase II study, ...
... American Diabetes Association,s 69th Scientific Sessions shows investigational ... function tests , , NEW ORLEANS, June ... Powder is a well-tolerated, ultra rapid acting insulin ... usual antidiabetic treatment, according to data presented today ...
Cached Medicine Technology:Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 2Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 3Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes 4AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 2AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA 3
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... The art ... experience. Learning from her grandmother’s side at a young age, Nasreen Zereshki was extremely ... has decided to share her cookbook Recipes from My Persian Kitchen with the world. ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... National Forest, to Ahjumawi Lava Springs, California’s northernmost and among its least visited ... untapped ground water aquifers, whose main outflow is at Ahjumawi Lava Springs, part ...
(Date:8/3/2015)... ... ... From 2006-2017 the number of dental laboratories in the ... for the National Association of Dental Laboratories ( NADL ) by Valmont Research ... As the number of dental laboratories decreases, dentists will have fewer options when ...
(Date:8/3/2015)... ... , ... Constantin Vasilica, 48 from Romania wanted to have an alternative healing ... years of suffering and using medications with strong side effects. This had already forced ... time off or wait longer hours in the waiting rooms. Instead, he went home ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... Code Council (ICC) announce an agreement to collaborate across a wide range ... to increasing building code knowledge among architects. , “Our combined membership, consisting of ...
Breaking Medicine News(10 mins):Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 2Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 3Health News:Medicine Lake Aquifer could ease California drought says fresh water advocate Sharon Kleyne – but is this necessary? 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 2Health News:Architects, International Code Council Ink Five-Year Collaborative Agreement 3
... suicidal thoughts as well, study finds , TUESDAY, June 9 ... bed at 10 p.m. are less apt to become depressed ... much later, recent research shows. , "This study bolsters the ... study author James Gangwisch, an assistant professor of psychiatry at ...
... LANCASTER, Pa., June 9 Herley Industries, Inc. (Nasdaq: ... Lancaster division received a contract award valued at approximately ... manufacture complex Integrated Microwave Assemblies (IMA) for an electronic ... Herley Chairman and CEO, Myron Levy, said, "Herley has ...
... professional pilots for example, depend on good vision as ... not required to undergo regular vision testing. A new ... they don,t recall ever having their vision tested or ... last vision exam. The study, performed at ...
... This release is available in French . ... antifungals are seeping into the waterways of North America, ... in the peer-reviewed journal Environmental Health Perspectives ... researchers, the review found that consumption of anti-infectives for ...
... unions, and veteran political leaders announces support for ... improve outcomes and reduce health care costs for ... support bipartisan reform agreement in Congress , ... an organization bringing together an expanding alliance of ...
... First Sugar-Free Functional Beverage Made Specifically for Kids, Over Soda ... WAT-AAH!, the first sugar-free functional beverage brand made specifically for ... their first nationwide WAT-AAH! Challenge to defy the expectation that ... over water. , , During the months of ...
Cached Medicine News:Health News:Early Bedtime May Help Stave Off Teen Depression 2Health News:Early Bedtime May Help Stave Off Teen Depression 3Health News:Herley Receives a $1.2 Million Contract Award for Complex Integrated Microwave Assemblies for U.S. Electronic Attack Aircraft 2Health News:Antibiotics, antimicrobials and antifungals in waterways 2Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 2Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 3Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 4Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 5Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 6Health News:Businesses, Unions, Veteran Party Leaders Unite Behind Bipartisan, Consensus Approach to Health Care Reform 7Health News:Let Water Be Water, LLC Announces Results of the 'WAT-AAH! Challenge' 2
The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
Indicated to facilitate the intra-luminal placement of conventional guidewires beyond stenotic lesions, including chronic total coronary occlusions....
... Para 12 is a three-part differential control assayed ... STKR, J Series, T Series, AcT/AcT diff/AcT diff2, ... 1500, 1600, 1700, and 1800; Danam Datacell18, Datacell ... I-1800, I-1800MS/MS PLUS and I-1600; the ABX Micros ...
... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
Medicine Products: